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Inﬂammation and mutation of the tumor suppressor p53 are two apparently unrelated conditions that are strongly
associated with cancer initiation and progression. We recently reported that gain-of-function mutant p53 modiﬁes the
response of cancer cells to inﬂammatory signals by binding a cytoplasmic tumor suppressor protein involved in TNFa
signaling.
The tumor suppressor gene TP53 is
frequently mutated in cancer, and mis-
sense p53 mutants (mutp53) are stable
proteins that may acquire novel poten-
tially oncogenic activities (gain-of-func-
tion or GOF mutants).1
Various lines of evidence link p53
mutation to proinflammatory behavior of
cancer cells. In particular, mutp53 can
enhance nuclear factor kappa-B (NF-kB)
activity in response to the proinflamma-
tory cytokine tumor necrosis factor a
(TNFa/, and a correlation between
nuclear p65 NF-kB (RelA) staining and
mutant p53 can be observed in cancer
samples.2 Most notably, a recent study
demonstrated that germline p53 mutation
dramatically accelerates colon cancer in a
mouse model of colitis.3 The latter work
provided evidence that mutp53 sustains
NF-kB activity in conditions of chronic
TNFa stimulation, and concluded that
p53 mutation predisposes to colitis-related
cancer by enforcing and maintaining a
proinflammatory microenvironment that
favors cell transformation. Conceptually,
this conclusion may be extended to other
chronic inflammatory conditions.
Considering that mutation of p53
often occurs at later stages during tumori-
genesis, we speculated that p53 mutations
might also affect inflammation-dependent
progression and aggressiveness of already
initiated cancers. Indeed, we observed that
metastatic cancer cell lines with various
p53 point mutations respond to an
inflammatory milieu by increasing their
invasive behavior.4 We confirmed that
mutp53 amplifies TNF-induced expres-
sion of NF-kB target genes, but we also
noticed that mutp53 dampens expression
of TNF-inducible genes that depend on
the ASK1 (apoptosis signal-regulating
kinase)/JNK (c-Jun N-terminal kinase)/
AP-1 (transcription factor AP-1) axis.
Previous studies reported that mutp53
binds to the promoters of inflammatory
genes.2,3 We found that mutp53 also acts
at another level, directly downstream of
the TNF receptor, by physically interact-
ing with the tumor suppressor disabled
homolog-2 interacting protein (DAB2IP).
DAB2IP (also known as ASK1 interact-
ing protein [AIP1]) is a cytoplasmic Ras-
GTPase activating protein that also func-
tions as a signaling scaffold to modulate the
cell’s response to multiple oncogenic extra-
cellular signals, including TNFa.5,6 We
observed that mutp53 binds DAB2IP in
the cytoplasm, interfering with its physio-
logical interactions; this reduces TNF-
induced activation of the ASK1/JNK axis,
thereby promoting activation and nuclear
translocation of NF-kB (Fig. 1).
To conclusively define such nuclear-
independent mutp53 activity, we demon-
strated that a cytoplasmic mutant p53
(lacking nuclear localization signals) is suf-
ficient to mediate a proaggressive response
to inflammatory cytokines in cancer cells.
This is a paradigmatic example of cyto-
plasmic gain-of-function.
The idea that mutant p53 can have
cytoplasmic functions is plausible, but to
date has suffered from the lack of strong
experimental evidence; we think that our
data now provide convincing support for
this concept. Further support for cyto-
plasmic GOF is provided by the recent
demonstration that mutp53 can bind the
a subunit of AMP-activated protein
kinase (AMPK) in cancer cells, thus affect-
ing its functions.7 Mutant p53 is found in
variable but significant amounts in the
cytoplasm of cancer cells, and it is likely
that altered cellular localization—in addi-
tion to altered conformation—leads to the
formation of novel protein complexes.
Interestingly, p53 nonsense or frame-
shift mutations at positions immediately
before the nuclear localization signals are
found in human cancers (UMD TP53
mutation database, http://www.p53.fr).
Such mutants are predicted to encode
monomeric p53 proteins with normal
conformation of the DNA-binding
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domain, but a predominantly cyto-
plasmic localization. We previously
reported that DAB2IP can interact with
wild-type p53,8 therefore such mutants
could bind DAB2IP in the cytoplasm
and may have a specific oncogenic GOF
in an inflammatory context. This is an
intriguing hypothesis that we are cur-
rently exploring.
Another stimulating observation
emerged from in silico studies. Survival
analysis of breast cancer patients suggested
that tumors with mutant p53 are associ-
ated with a better outcome if they express
a group of genes (signature) that we have
linked to the TNF/mutp53 axis.4 At first
glance this observation seems paradoxical,
since the TNF/mutp53 axis promotes an
aggressive phenotype in cultured cells and
nude mice. We think this apparent contra-
diction reflects the influence of a parame-
ter that is missing in most experimental
models: the host immune system. In fact,
our data suggest that mutp53-modulated
activation of NF-kB endows cancer cells
with proinvasive and prosurvival activities
but, at the same time, triggers expression
of chemokines that can recruit leukocytes
to the tumor—a phenomenon that may
favor tumor elimination.9,10 In other
words, to unleash the tumorigenic forces
of NF-kB mutp53 necessarily exposes
cancer cells to the immune system, which
could dramatically affect the prognosis.
This hypothesis may open a number of
interesting perspectives. For instance, inte-
grating analysis of p53 mutation with the
immunoscore10 (i.e., quantity and type of
infiltrating immune cells) in cancer biop-
sies may improve prediction of the clinical
outcome in mammary tumors. Also, given
the double-edged effect of TNFa on can-
cer cells, the mutation status of p53 may
be used to help clinical choices in cancer
therapy.
Clearly, our observations also raise a
number of questions. According to our
analyses, mutp53 cancers expressing low
levels of chemokines linked to the TNF/
mutp53 axis tend to have a negative prog-
nosis. What happens in those cancers? Are
these cells less dependent on the NF-kB
activity for their survival/dissemination?
Or have they evolved a mechanism to
uncouple expression of oncogenic NF-kB
target genes from immunostimulatory
chemokines?
In vitro models and xenografts in
immunocompromised mice have allowed
us to explore the proinvasive and aggressive
side of this molecular axis and uncover part
of its mechanism. Now, the challenge is to
better understand the potential impact of
mutp53 in the complex interaction of can-
cer cells with the host immune system, and
possibly develop such knowledge into
strategies to improve therapy.
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